Physician profile
April Freeman
NPI 1144775206
$1,946.34
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $1,112 · 2023: $583 · 2024: $27.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $282.79 | 2021-2023 | Ozempic, Saxenda, Wegovy |
| Abbvie INC. | $244.90 | 2021-2024 | |
| Pfizer INC. | $229.41 | 2022-2023 | |
| Lilly USA, LLC | $195.48 | 2022-2023 | Emgality, Jardiance, Mounjaro |
| Amgen INC. | $141.29 | 2021-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.23 | 2021-2023 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $76.17 | 2022-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $72.60 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.49 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $63.47 | 2022-2023 | Rexulti |
| Arbor Pharmaceuticals, INC. | $54.32 | 2022 | |
| Glaxosmithkline, LLC. | $53.36 | 2021-2023 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $50.86 | 2022 | |
| Inogen, INC. | $44.64 | 2022 | |
| Astellas Pharma US INC | $43.96 | 2023-2024 | Veozah, Myrbetriq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $38.82 | 2022-2023 | Breztri |
| Sunovion Pharmaceuticals INC. | $34.25 | 2022 | |
| Idorsia Pharmaceuticals US INC | $31.19 | 2022-2023 | Quviviq |
| Currax Pharmaceuticals LLC | $29.79 | 2022 | |
| Amarin Pharma, INC. | $29.22 | 2022 | |
| Axsome Therapeutics, INC. | $16.34 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.